GENERAL ATLANTIC L P
Q2 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001017645
· CRD 133536
· SEC-registered investment adviser
$3.2B Reported Value Total
GENERAL ATLANTIC SERVICE COMPANY, L.P. reports 141 total accounts under management (AUM). There are 141 discretionary accounts valued at $85,091,746,390, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
429 funds
· $125.1B gross asset value
Private Equity Fund: $121.3B · Other: $3.7B · Real Estate Fund: $115.3M · Hedge Fund: $515.9K
Source: Form ADV filed 2026-08-12
Reported value
$3.2B
Quarter over quarter
-13.6%
Holdings
19
Top-10 concentration
94.2%
Key People
Form ADV owners & control persons
Gabriel Pierre Caillaux
CO-PRESIDENT AND MANAGING DIRECTOR OF GASC AND MEMBER OF THE PARTNERSHIP AND EXECUTIVE COMMITTEES OF GASC MGP
Martin Emiliano Escobari Lifchitz
CO-PRESIDENT AND MANAGING DIRECTOR OF GASC AND MEMBER OF THE PARTNERSHIP AND EXECUTIVE COMMITTEES OF GASC MGP
William Edward Ford
CHAIRMAN, CEO AND MANAGING DIRECTOR OF GASC AND MEMBER OF THE PARTNERSHIP AND EXECUTIVE COMMITTEES OF GASC MGP
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $3.2B |
| Positions | 19 |
| Change in reported value | -26.2% |
| New positions | 0 |
| Exited positions | 3 |
| Position turnover | 13.6% |
| Top-10 concentration | 94.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $2.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
12 | $2.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $2.9B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
16 | $3.3B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
15 | $3.6B |
|
Q1 2025 13F
Filed May 14, 2025
|
15 | $3.0B |
|
Q4 2024 13F
Filed Feb 7, 2025
|
16 | $2.8B |
|
Q3 2024 13F
Filed Nov 12, 2024
|
18 | $3.5B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
19 | $3.2B |
|
Q1 2024 13F
Filed May 15, 2024
|
22 | $4.3B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
26 | $7.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
29 | $6.5B |
|
Q2 2023 13F
Filed Aug 11, 2023
|
30 | $6.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
31 | $8.6B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
33 | $7.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $8.5B |
|
Q2 2022 13F
Filed Aug 12, 2022
|
38 | $7.7B |
|
Q1 2022 13F
Filed May 16, 2022
|
35 | $10.9B |
|
Q4 2021 13F
Filed Feb 11, 2022
|
32 | $13.0B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
25 | $17.1B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 19 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | XP XP, INC | $521.0M | 16.38% |
| 2 | DLO DLOCAL | $517.0M | 16.26% |
| 3 | ALKT ALKAMI | $489.5M | 15.39% |
| 4 | ALHC ALIGNMENT HEALTHCARE | $477.0M | 15.0% |
| 5 | SQSP SQUARESPACE | $463.0M | 14.56% |
| 6 | PHVS PHARVARIS | $141.6M | 4.45% |
| 7 | EWCZ EUROPEAN WAX CENTER | $130.2M | 4.09% |
| 8 | AKRO AKERO THERAPEUTICS | $122.8M | 3.86% |
| 9 | CNTA CENTESSA PHARMACEUTICALS | $87.4M | 2.75% |
| 10 | BLND BLEND LABS | $45.2M | 1.42% |
| 11 | IMCR IMMUNOCORE | $42.8M | 1.34% |
| 12 | RPRX ROYALTY PHARMA | $39.6M | 1.24% |
| 13 | THRD THIRD HARMONIC BIO | $38.5M | 1.21% |
| 14 | RSKD RISKIFIED | $34.0M | 1.07% |
| 15 | SLRN ACELYRIN | $12.7M | 0.4% |
| 16 | OPEN OPENDOOR | $11.6M | 0.37% |
| 17 | LOGC WISH | $3.5M | 0.11% |
| 18 | GROV GROVE COLLABORATIVE | $1.7M | 0.05% |
| 19 | ADAG ADAGENE | $807.8K | 0.03% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.